20 
Dr. Mortimer explained it is almost inpossible to do genetics on most 
industrial strains. Seme strains are triploid or higher ploidy. Indus- 
trial strains usually either fail to sporulate or, if they do sporulate, 
the spores have extremely lew viability. Physiological and morphological 
criteria must therefore be used for identification. 
Dr. Talbot doubted the NIH Director would approve a reconmendat ion to 
exenpt all Saccharonyces species since such a proposal had not been pub- 
lished in the Federal Register for public ccrrment . 
Dr. Pramer moved acceptance of the BidTechnica International, Inc., request 
as it appeared in the August 19, 1985, Federal Register . The motion was 
seconded by Dr. Cohen. 
By a vote of seventeen in favor, none opposed, and no abstentions, the 
RAC recormended acceptance of the proposal as it appeared in the Federal 
Register . 
Dr. Walters suggested RAC might establish a working group to evaluate the 
proposal to exenpt all Saccharcmyces species from the NIH Guidelines. 
Drs. Davis and Pramer did not favor establishment of such a working group 
at this time. 
VI. PROPOSED AMENDMENT OF PART III OF TOE NIH GUIDELINES 
Dr. Johnson said Dr. Bernard Talbot, Deputy Director of the National Insti- 
tute of Allergy and Infectious Diseases, in a memorandum (tab 1240) dated 
February 12, 1985, noted that under the NIH Guidelines certain proposals 
are received for review by the NIH RAC and approval by NIH. Recently 
other Federal agencies have taken steps toward assuming new roles in the 
review of recombinant DNA proposals. Because of these developments, a 
proposal submitted to the NIH for RAC review and NIH approved, may also be 
submitted to another Federal agency for review. 
Dr. Talbot had written: 
"In such a case, I believe it would be advantageous for NIH to have the 
option of deferring to the review and approval by the other Federal 
agency rather them always going through review and approved, by both the 
other Federal agency and the NIH. In order to allcw this, I request 
that the following proposed change in the NIH Guidelines be issued for 
cement, and placed on the agenda of the next RAC meeting. I propose 
that a new sentence be added at the end of Section III-A of the Guide- 
lines ( 'Experiments that Require RAC Review and NIH and IBC Approval 
Before Initiation' ) just before Section III-A-1 of the Guidelines as 
follows: 
[402] 
